WO2010017433A3 - Use of sucralose as a granulating agent - Google Patents

Use of sucralose as a granulating agent Download PDF

Info

Publication number
WO2010017433A3
WO2010017433A3 PCT/US2009/053077 US2009053077W WO2010017433A3 WO 2010017433 A3 WO2010017433 A3 WO 2010017433A3 US 2009053077 W US2009053077 W US 2009053077W WO 2010017433 A3 WO2010017433 A3 WO 2010017433A3
Authority
WO
WIPO (PCT)
Prior art keywords
sucralose
granulating agent
granulation
mixture
forming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/053077
Other languages
French (fr)
Other versions
WO2010017433A2 (en
Inventor
Christopher E. Szymczak
Ryan Snyder
Kristin Costello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenvue Brands LLC
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Priority to AU2009279521A priority Critical patent/AU2009279521A1/en
Priority to BRPI0917026A priority patent/BRPI0917026A2/en
Priority to CA2732105A priority patent/CA2732105A1/en
Priority to CN2009801311058A priority patent/CN102112114A/en
Priority to EP09791261A priority patent/EP2328558A2/en
Priority to MX2011001487A priority patent/MX2011001487A/en
Publication of WO2010017433A2 publication Critical patent/WO2010017433A2/en
Publication of WO2010017433A3 publication Critical patent/WO2010017433A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

A method of making a granulation comprising the steps of (a) combining sucralose, a polar solvent, a wettable material and an active agent, thereby forming a mixture; and (b) drying the mixture, thereby forming the granulation.
PCT/US2009/053077 2008-08-08 2009-08-07 Use of sucralose as a granulating agent Ceased WO2010017433A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2009279521A AU2009279521A1 (en) 2008-08-08 2009-08-07 Use of sucralose as a granulating agent
BRPI0917026A BRPI0917026A2 (en) 2008-08-08 2009-08-07 use of sucralose as a granulating agent
CA2732105A CA2732105A1 (en) 2008-08-08 2009-08-07 Use of sucralose as a granulating agent
CN2009801311058A CN102112114A (en) 2008-08-08 2009-08-07 Use of sucralose as a granulating agent
EP09791261A EP2328558A2 (en) 2008-08-08 2009-08-07 Use of sucralose as a granulating agent
MX2011001487A MX2011001487A (en) 2008-08-08 2009-08-07 Use of sucralose as a granulating agent.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8731108P 2008-08-08 2008-08-08
US61/087,311 2008-08-08

Publications (2)

Publication Number Publication Date
WO2010017433A2 WO2010017433A2 (en) 2010-02-11
WO2010017433A3 true WO2010017433A3 (en) 2010-06-24

Family

ID=41653160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/053077 Ceased WO2010017433A2 (en) 2008-08-08 2009-08-07 Use of sucralose as a granulating agent

Country Status (8)

Country Link
US (1) US20100034894A1 (en)
EP (1) EP2328558A2 (en)
CN (1) CN102112114A (en)
AU (1) AU2009279521A1 (en)
BR (1) BRPI0917026A2 (en)
CA (1) CA2732105A1 (en)
MX (1) MX2011001487A (en)
WO (1) WO2010017433A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278913A1 (en) * 2009-04-30 2010-11-04 Sancilio & Company Chewable tablet
KR20150043548A (en) 2009-10-01 2015-04-22 앱탈리스 파마테크, 인코포레이티드 Orally administered corticosteroid compositions
US10687547B2 (en) 2012-02-15 2020-06-23 Kraft Foods Group Brands Llc Compositions and methods for inhibiting precipitation of dyes in a beverage
US11013248B2 (en) 2012-05-25 2021-05-25 Kraft Foods Group Brands Llc Shelf stable, concentrated, liquid flavorings and methods of preparing beverages with the concentrated liquid flavorings
CN103239412A (en) * 2013-05-15 2013-08-14 北京科源创欣科技有限公司 Pharmaceutical composition comprising loperamide or hydrochloride thereof and preparation method thereof
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
LT2886108T (en) 2013-12-23 2019-03-25 Dr. Falk Pharma Gmbh Optimised pharmaceutical formula for the treatment of inflammatory changes of the esophagus
WO2016164464A1 (en) * 2015-04-07 2016-10-13 Church & Dwight Co., Inc. Multicomponent gummy compositions with hard core
TWI777515B (en) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 Methods of treating eosinophilic esophagitis
CN106521561B (en) * 2016-11-01 2019-05-28 攀钢集团钛业有限责任公司 The method of closing down magnesium electrolysis bath assembly line and molten magnesium ingot
JP6639034B2 (en) * 2018-06-13 2020-02-05 大原薬品工業株式会社 Orally disintegrating tablets with improved ingestibility, containing granules containing a flavoring agent
CN111450068B (en) * 2019-01-21 2025-10-17 江苏先声药业有限公司 Sevelamer carbonate pharmaceutical composition and preparation method thereof
US12691128B2 (en) 2019-10-01 2026-07-28 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and reducing candidiasis
CN116555499A (en) * 2022-04-13 2023-08-08 浙江贝灵生物医药有限公司 Compressible sucrose particles and method for preparing same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030883A1 (en) * 2001-10-12 2003-04-17 Kosmos Pharma Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
EP1878426A1 (en) * 2005-04-26 2008-01-16 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation containing biguanide compound
WO2008013808A2 (en) * 2006-07-24 2008-01-31 Cima Labs Inc. High dose orally dissolvable/disintegrable lyophilized dosage form
WO2009086046A1 (en) * 2007-12-21 2009-07-09 Eurand, Inc. Orally disintegrating tablet compositions of temazepam

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US5271946A (en) * 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5136031A (en) * 1990-07-09 1992-08-04 Tate & Lyle Public Limited Company Chlorination of sugars
EP0782449B1 (en) * 1994-09-22 2003-04-09 Akzo Nobel N.V. Process of making dosage units by wet granulation
US5498709A (en) * 1994-10-17 1996-03-12 Mcneil-Ppc, Inc. Production of sucralose without intermediate isolation of crystalline sucralose-6-ester
DE19617487A1 (en) * 1996-05-02 1997-11-06 Merck Patent Gmbh Taste improvement of active pharmaceutical ingredients
JP3735426B2 (en) * 1996-12-11 2006-01-18 株式会社東芝 Nonvolatile semiconductor memory device and manufacturing method thereof
US7799342B2 (en) * 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
US20020122823A1 (en) * 2000-12-29 2002-09-05 Bunick Frank J. Soft tablet containing dextrose monohydrate
US20070178150A1 (en) * 2003-07-10 2007-08-02 Prasad Adusumilli Pharmaceutical compositions
US8062659B2 (en) * 2004-02-20 2011-11-22 Novartis Ag Dietary fiber composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030883A1 (en) * 2001-10-12 2003-04-17 Kosmos Pharma Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
EP1878426A1 (en) * 2005-04-26 2008-01-16 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation containing biguanide compound
WO2008013808A2 (en) * 2006-07-24 2008-01-31 Cima Labs Inc. High dose orally dissolvable/disintegrable lyophilized dosage form
US20080031947A1 (en) * 2006-07-24 2008-02-07 Cima Labs Inc. Orally dissolvable/disintegrable lyophilized dosage forms containing protected
WO2009086046A1 (en) * 2007-12-21 2009-07-09 Eurand, Inc. Orally disintegrating tablet compositions of temazepam

Also Published As

Publication number Publication date
BRPI0917026A2 (en) 2016-02-16
CA2732105A1 (en) 2010-02-11
AU2009279521A1 (en) 2010-02-11
MX2011001487A (en) 2011-03-30
WO2010017433A2 (en) 2010-02-11
EP2328558A2 (en) 2011-06-08
US20100034894A1 (en) 2010-02-11
CN102112114A (en) 2011-06-29

Similar Documents

Publication Publication Date Title
WO2009050289A3 (en) Solid dispersion product containing n-aryl urea-based compound
WO2010125470A3 (en) Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2007146549A3 (en) Achieving power savings through packet grouping
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
WO2008110308A3 (en) Novel herbicides
WO2012003367A3 (en) Method for delivering an active agent
WO2007147010A3 (en) Implantable medical devices and methods for making the same
WO2007095101A3 (en) Selective removal chemistries for semiconductor applications, methods of production and uses thereof
WO2006131721A3 (en) Topical ungual formulations
WO2007109605A3 (en) Pharmaceutical compositions
WO2009046696A3 (en) Material system and method for changing properties of a plastic component
WO2007011739A3 (en) Polymers with low band gaps and high charge mobility
WO2006110551A3 (en) Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
WO2008092615A3 (en) Herbicidal composition comprising pinoxaden
WO2007010400A3 (en) Gastroretentive formulations and manufacturing process thereof
WO2010116256A3 (en) Thinning agent
WO2009117130A3 (en) Extended release forumulation containing a wax
WO2009042114A3 (en) Phenazine derivatives and uses thereof
WO2007112339A3 (en) Granular formulation
WO2010117738A3 (en) Solid state forms of sitagliptin salts
WO2007002376A3 (en) Method of preparing electrode
MX336276B (en) Surfactant compositions and use for aqueous compositions.
WO2006085957A3 (en) Polymeric nanocomposites and processes for making the same
WO2005096744A3 (en) Oriented polymer fibers and methods for fabricating thereof
WO2008131280A3 (en) Ablation device

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980131105.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09791261

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2732105

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009279521

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/001487

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009279521

Country of ref document: AU

Date of ref document: 20090807

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2009791261

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009791261

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0917026

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110208